Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma: a Phase 2 Study. (ChromoKey)
An Open-label, Multicenter, Phase 2 Study of First-line Lenvatinib Plus Pembrolizumab and Later-line Lenvatinib Plus Everolimus in Patients With Metastatic Chromophobe Renal Cell Carcinoma.
Chromophobe renal cell carcinoma (chRCC) accounts for approximately 5% of RCC cases and has distinct morphological and molecular features. However, advanced chRCC follows an aggressive clinical course and responds poorly to standard regimens developed for clear cell RCC.
Lenvatinib plus everolimus (LEN+EVE) has demonstrated clinical activity in clear cell RCC (Study 205), with responses also reported in non-clear cell subtypes, including chRCC. Lenvatinib plus pembrolizumab (LEN+PEMBRO) demonstrated a high objective response rate (ORR) in KEYNOTE-B61, including in the chRCC subgroup.
These findings support conducting a prospective phase 2 study specifically dedicated to this rare subtype to provide direct evidence of the efficacy and safety of these two active combinations.
研究概览
地位
地位
干预/治疗
干预/治疗
详细说明
ChromoKey is a prospective, open-label, multicenter, two-cohort, non-randomized phase 2 study evaluating the efficacy and safety of first-line lenvatinib plus pembrolizumab (Cohort A) and later-line lenvatinib plus everolimus (Cohort B) in patients with metastatic chromophobe renal cell carcinoma (chRCC).
The study enrolls 40 patients across two independent cohorts, with 20 patients in each cohort. Eligible patients are adults with histologically confirmed metastatic chRCC, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3, and measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Patients from all International Metastatic RCC Database Consortium (IMDC) risk groups are eligible.
Cohort A includes patients who have received no previous systemic therapy for metastatic disease. Patients receive lenvatinib 20 mg orally once daily in combination with pembrolizumab 200 mg intravenously every 3 weeks.
Cohort B includes patients whose disease progresses following previous systemic therapy and who have not previously received lenvatinib. Patients receive lenvatinib 18 mg orally once daily in combination with everolimus 5 mg orally once daily. Treatment continues until disease progression or unacceptable toxicity.
The primary endpoint is the objective response rate in each cohort, defined as the proportion of patients achieving a complete or partial response according to RECIST version 1.1.
Secondary endpoints include progression-free survival, overall survival, duration of response, and safety. Tumor response is evaluated using radiological assessments, and safety is assessed through monitoring of adverse events, clinical examinations, and laboratory investigations.
Each cohort is evaluated independently to characterize the activity and tolerability of the respective combination in its treatment setting. The study does not include randomization or a formal comparison between the two cohorts.
研究类型
研究类型
注册 (估计的)
注册
阶段
阶段
- 阶段2
联系人和位置
学习联系方式
学习联系方式
- 姓名:Ilya Tsimafeyeu
- 电话号码:+74999054690
- 邮箱:bucare@bucare.org
学习地点
-
-
-
Chelyabinsk、俄罗斯
- 招聘中
- Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
-
接触:
- Natalia Glushankova
- 电话号码:+74999054690
- 邮箱:sten_to@mail.ru
-
Krasnoyarsk、俄罗斯
- 招聘中
- V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University
-
接触:
- Ruslan Zukov
- 电话号码:+74999054690
- 邮箱:sten_to@mail.ru
-
Orenburg、俄罗斯
- 招聘中
- Orenburg Regional Cancer Center
-
接触:
- Makhabbat Murzalina
- 电话号码:+74999054690
- 邮箱:sten_to@mail.ru
-
Saint Petersburg、俄罗斯
- 招聘中
- Dr. Berezin Medical Institute
-
接触:
- Grigory Raskin
- 电话号码:+74999054690
- 邮箱:sten_to@mail.ru
-
Saint Petersburg、俄罗斯
- 招聘中
- SBHI Leningrad regional clinical hospital, Saint-Petersburg
-
接触:
- Andrei Lebedinets
- 电话号码:+74999054690
- 邮箱:sten_to@mail.ru
-
Saratov、俄罗斯
- 招聘中
- Saratov Regional Cancer Center
-
接触:
- Svetlana Averianova
- 电话号码:+74999054690
- 邮箱:sten_to@mail.ru
-
Ufa、俄罗斯
- 招聘中
- Republican Clinical Oncology Dispensary
-
接触:
- Alexander Sultanbaev
- 电话号码:+74999054690
- 邮箱:sten_to@mail.ru
-
Yekaterinburg、俄罗斯
- 招聘中
- Sverdlovskiy Regional Oncological Dispensary
-
接触:
- Marina Zafirova
- 电话号码:+74999054690
- 邮箱:sten_to@mail.ru
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Histologically confirmed chromophobe renal cell carcinoma.
- Measurable disease according to RECIST version 1.1.
- ECOG performance status of 0-3.
- Cohort A: No prior systemic therapy for metastatic disease.
- Cohort B: Disease progression following prior systemic therapy and no previous exposure to lenvatinib
- Adequate bone marrow, hepatic, and renal function.
- Signed informed consent.
Exclusion Criteria:
- Uncontrolled or symptomatic central nervous system metastases or leptomeningeal disease.
- Uncontrolled hypertension despite appropriate antihypertensive treatment.
- Clinically significant uncontrolled cardiovascular disease.
- Active infection requiring systemic treatment.
- Active clinically significant bleeding or a high risk of severe hemorrhage.
- Major surgery without adequate postoperative recovery or a serious non-healing wound.
- Gastrointestinal conditions that significantly impair the absorption of oral study medications.
- Known severe hypersensitivity to any component of the assigned study treatment.
- Current pneumonitis or interstitial lung disease.
- Pregnancy or breastfeeding.
- Any medical or psychiatric condition that, in the investigator's judgment, compromises patient safety or adherence to study procedures.
- Cohort A only: Active autoimmune disease requiring systemic immunosuppressive treatment, or a requirement for chronic systemic immunosuppression, excluding physiological corticosteroid replacement.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:Cohort A: first-line lenvatinib plus pembrolizumab
lenvatinib 20 mg orally once daily in combination with pembrolizumab 200 mg intravenously every 3 weeks |
tablets solution |
|
实验性的:Cohort B: later-line lenvatinib plus everolimus
lenvatinib 18 mg orally once daily in combination with everolimus 5 mg orally once daily |
tablets tablets |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Objective response rate
大体时间:12 months
|
the proportion of patients achieving a complete or partial response according to RECIST version 1.1 |
12 months
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
progression-free survival
大体时间:24 months
|
the time from treatment initiation to the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first. |
24 months
|
|
overall survival
大体时间:24 months
|
the time from treatment initiation to death from any cause |
24 months
|
|
duration of response
大体时间:24 months
|
the time from the first documented complete or partial response to disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first |
24 months
|
|
Grade 3 and higher treatment-emergent adverse events
大体时间:24 months
|
the proportion of patients experiencing at least one treatment-emergent adverse event of grade 3 or higher according to NCI CTCAE version 5.0. |
24 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
其他研究编号
- ChromoKey
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Study results are disseminated through scientific publications and conference presentations in aggregate form.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.